Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ever Fortune.AI Co (ROCO:6841) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Ever Fortune.AI Co Forward PE Ratio Related Terms
Ever Fortune.AI Co Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Ever Fortune.AI Co's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ever Fortune.AI Co Forward PE Ratio Chart
Ever Fortune.AI Co Annual Data
Trend
2025-12
Forward PE Ratio
76.93
Ever Fortune.AI Co Quarterly Data
2025-06
2025-12
2026-03
Forward PE Ratio
149.13
76.93
70.45
ROCO:6841 vs VEEV, BTSG, HQY: Forward PE Ratio Comparison
For the Health Information Services subindustry, Ever Fortune.AI Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ever Fortune.AI Co Forward PE Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Ever Fortune.AI Co's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Ever Fortune.AI Co's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Ever Fortune.AI Co (ROCO:6841) has a Forward PE Ratio of 60.45 as of Aug. 17, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Ever Fortune.AI Co and its competitors. According to the industry distribution chart, Ever Fortune.AI Co ranks #283 out of 315 companies in the Healthcare Providers & Services industry, placing it in the top 89.8%.
Is Ever Fortune.AI Co's Forward PE Ratio too high?
Ever Fortune.AI Co's current Forward PE Ratio is 60.45. The Healthcare Providers & Services industry median Forward PE Ratio is 18.93. Ever Fortune.AI Co's value of 60.45 is 219.3% above this industry median. Based on the distribution chart, Ever Fortune.AI Co ranks #283 out of 315 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Ever Fortune.AI Co has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ever Fortune.AI Co's Forward PE Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Ever Fortune.AI Co ranks #283 out of 315 companies for Forward PE Ratio. This places Ever Fortune.AI Co in the lower half of its industry. The industry median Forward PE Ratio is 18.93. Ever Fortune.AI Co's value of 60.45 is 219.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Healthcare Providers & Services company?
The median Forward PE Ratio among Healthcare Providers & Services companies is 18.93, based on 315 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ever Fortune.AI Co's current Forward PE Ratio of 60.45 is 219.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Ever Fortune.AI Co and its competitors. For the Healthcare Providers & Services industry, the median Forward PE Ratio is 18.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ever Fortune.AI Co's current Forward PE Ratio is 60.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ever Fortune.AI Co stock overvalued right now?
Based on GuruFocus' analysis, Ever Fortune.AI Co (ROCO:6841) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$144.59, compared to a current price of NT$52.40 — trading 63.8% below its estimated fair value. The current Forward PE Ratio is 60.45 and 219.3% above the Healthcare Providers & Services industry median of 18.93. Ever Fortune.AI Co's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Ever Fortune.AI Co (ROCO:6841), the current Forward PE Ratio is 60.45 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ever Fortune.AI Co (ROCO:6841) Overvalued in 2026?
Based on GuruFocus' analysis, Ever Fortune.AI Co stock appears to be undervalued.
The current stock price of NT$52.40 is trading 63.8% below its estimated GF Value™ of NT$144.59.
GuruFocus considers Ever Fortune.AI Co to be Significantly Undervalued.
Key valuation signals for ROCO:6841:
Forward PE Ratio: 60.45
GF Value™: NT$144.59 vs. price of NT$52.40 (63.8% below fair value)
Industry Position: 219.3% above the Healthcare Providers & Services median (#283 of 315)
No single metric tells the full story. See the ROCO:6841 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ever Fortune.AI Co Ltd is composed of establishing a cloud medical platform based on medical Big data, and to provide customized medical artificial intelligence solutions and services in various biomedical fields. The results both provide a professional second opinion for doctors and assist clinical doctors in making a medical diagnosis, which in turn raises the speed, accuracy, and efficiency of medical decisions. The products of the company include: Medical Artificial Intelligence, Cloud Biomedical Platform, and Medical Big Data. Its segments are: Medical AI Department; Biotechnology Department; and Others, where maximum revenue is derived from Biotechnology Department segment. Geographically, it operates in Taiwan, U.S.A., and Vietnam, of which maximum revenue is generated from Taiwan.
75GF Score
Get the complete analysis for ROCO:6841
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6841 has been successfully added to your 
